Enzyme

Global Protein Labeling Market Report to 2028 - Featuring Thermo Fisher Scientific, Merck and PerkinElmer Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022 - 5:10pm

The "Global Protein Labeling Market Size, Share & Industry Trends Analysis Report By Method, By Product, By Application, By Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Protein Labeling Market Size, Share & Industry Trends Analysis Report By Method, By Product, By Application, By Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global Protein Labeling Market size is expected to reach $3.2 billion by 2028, rising at a market growth of 7.5% CAGR during the forecast period.
  • As a result, proteomics and protein chemistry is being used to investigate the protein binding mechanism.
  • Covalent protein labeling makes imaging mammalian proteins in living cells easier and more versatile, as well as allowing for protein capture in vitro.

Active Ingredients for Cosmetics Global Market Report 2022: Demand for Cosmetic Products amidst Rising Consumer Desire to Look Good Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022 - 1:11pm

The market for active ingredients in cosmetic products is being fueled by the escalating demand for sun protection, anti-aging and skin whitening products.

Key Points: 
  • The market for active ingredients in cosmetic products is being fueled by the escalating demand for sun protection, anti-aging and skin whitening products.
  • The global cosmetic active ingredients market will also be driven by the growing interest of male consumers in personal grooming and grooming products.
  • The positive outlook market is encouraging manufacturers to focus on R&D initiatives to develop new products featuring unique ingredients, thus driving growth in the cosmetic active ingredients market.
  • Leading players operating in the cosmetic active ingredients market are adopting strategies such as new product development, mergers, acquisitions and expansions to strengthen market presence.

DGAP-News: Is BioLife Sciences (OTCPK: BLFE) An OTC Company Primed For Growth?

Retrieved on: 
Tuesday, August 16, 2022 - 7:05pm

Is BioLife Sciences (OTCPK: BLFE) An OTC Company Primed For Growth?

Key Points: 
  • Is BioLife Sciences (OTCPK: BLFE) An OTC Company Primed For Growth?
  • BioLife Sciences Inc. (BioLife), a commercialization accelerator, licensor and developer of technologies, has reportedly provided investors with a significant company update throughout the course of a two-year transformation.
  • Lets take a look at some of what the company has been up to over the last two years.
  • In February of 2022, BioLife completed the acquisition of Health Box LLC an Arizona-based orthomolecular medicine and natural health products company.

Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office

Retrieved on: 
Tuesday, August 16, 2022 - 2:00pm

Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a Notice of Allowance has been received from the European Patent Office (EPO) for claims involving compositions of proenzymes to treat cancer.

Key Points: 
  • Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a Notice of Allowance has been received from the European Patent Office (EPO) for claims involving compositions of proenzymes to treat cancer.
  • A third patent application is currently under examination at the EPO for a method to treat cancer stem cells, which was allowed in March this year by the US Patent and Trademark Office (USPTO).
  • The field of the invention covers future dosing in planned clinical studies for the Companys lead product candidate, PRP.
  • The allowed patent, citing proenzyme compositions to treat cancer, comprising trypsinogen and chymotrypsinogen at specific higher dosage ratios than the Companys original foundation patent, will enable the Company to cover higher doses in a planned, Phase I, First-In-Human study in advanced cancer patients.

Resilience Announces Collaboration to Manufacture and Deliver Biotherapeutics for Rare and Complex Conditions

Retrieved on: 
Monday, August 15, 2022 - 4:00pm

National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced a strategic collaboration with Mayo Clinic in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions.

Key Points: 
  • National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced a strategic collaboration with Mayo Clinic in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions.
  • Resilience will collaborate with Mayos Center for Regenerative Medicine in Two Discovery Square, located within the research corridor of the Destination Medical Center economic development initiative in Rochester, Minnesota.
  • Resilience and Mayo will build embedded process and analytical development labs, as well as quality control labs.
  • This embedded approach allows for closer proximity and collaboration to jointly develop and progress cell therapies and other advanced modalities into clinical care.

$8.3 Bn Industrial Enzymes (Carbohydrases [Amylases, Cellulases], Proteases, Lipases) Markets - Global Forecast to 2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, August 12, 2022 - 12:53pm

The "Industrial Enzymes Market by Type ; Source ; Form ; Application - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Industrial Enzymes Market by Type ; Source ; Form ; Application - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The industrial enzymes market is expected to grow at a CAGR of 6.5% from 2022 to 2029 to reach $8.30 billion by 2029.
  • Based on type, the industrial enzymes market is segmented into carbohydrases, proteases, lipases, and others.
  • In 2022, the liquid form segment is expected to account for the larger share of the industrial enzymes market.

Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia

Retrieved on: 
Thursday, August 11, 2022 - 11:35pm

CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced that data from the core period of the open-label, Phase 2 study of PYRUKYND® (mitapivat) in adults with non-transfusion-dependent α- or β-thalassemia were published on August 11, 2022, in The Lancet. Data from this study were previously presented at the 2021 European Hematology Association (EHA) Annual Congress. PYRUKYND® is a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase (PK) enzymes.

Key Points: 
  • Data from this study were previously presented at the 2021 European Hematology Association (EHA) Annual Congress.
  • PYRUKYND is a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase (PK) enzymes.
  • These data demonstrate the potential clinical benefits of mitapivat for a broad spectrum of thalassemia patients and support its continued investigation in pivotal trials.
  • One patient who had -thalassemia discontinued after Week 4 due to a treatment-emergent adverse event deemed unrelated to the study drug.

Xinteza Unveils Disruptive Non-Cannabaceae Source for Cannabinoid Biosynthesis in Breakthrough Research Led by Prof. Asaph Aharoni at the Weizmann Institute of Science

Retrieved on: 
Thursday, August 11, 2022 - 3:01pm

The company's IP portfolio is based on a license signed with Yeda, the commercial arm of the Weizmann Institute of Science.

Key Points: 
  • The company's IP portfolio is based on a license signed with Yeda, the commercial arm of the Weizmann Institute of Science.
  • Biosynthesis technologies have the potential to revolutionize cultivation-and-extraction-based production methods of cannabinoid compounds for CPG and pharma.
  • Xinteza holds an exclusive license for both cannabinoids and psychoactives from the Weizmann Institute of Science with research led by Prof. Asaph Aharoni and is diligently building an unprecedented portfolio of dozens of related IP assets and patents.
  • Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science.

Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments

Retrieved on: 
Wednesday, August 10, 2022 - 9:00pm

Mr. Emalfarb continued, The Company now has commercial agreements in each of its three core verticals: Human Health, Animal Health, and Alternative Proteins.

Key Points: 
  • Mr. Emalfarb continued, The Company now has commercial agreements in each of its three core verticals: Human Health, Animal Health, and Alternative Proteins.
  • On July 22, 2022, the Company submitted its Clinical Trial Application (CTA) to the South African Health Products Regulatory Authority (SAHPRA) for expedited review.
  • Phibro/Abic Animal Health On February 10, 2022, Dyadic entered into an exclusive license agreement for a Phibro/Abic targeted disease.
  • Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise.

Digestive Health Products Market Size Worth $89.9 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Tuesday, August 9, 2022 - 3:30pm

Rising geriatric population, increasing healthcare costs, changing lifestyle, and innovation in formulations of digestive health products are primary factors that have contributed towards market growth.

Key Points: 
  • Rising geriatric population, increasing healthcare costs, changing lifestyle, and innovation in formulations of digestive health products are primary factors that have contributed towards market growth.
  • Read 135-page full market research report for more Insights, " Digestive Health Products Market Size, Share & Trends Analysis Report By Ingredient (Prebiotics, Probiotics, Food Enzymes), By Product (Dairy Products, Bakery & Cereals, Non-alcoholic Beverages), By Region, And Segment Forecasts, 2022 - 2030 ", published by Grand View Research.
  • Additionally, increasing demand for natural and safe products is further expected to bolster the demand for digestive health products.
  • Grand View Research has segmented the global digestive health products market on the basis of ingredient, product, and region:
    Digestive Health Products Market - Ingredient Outlook(Revenue, USD Million, 2017 - 2030)